NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- HACOR score efficacy
Study Overview
Brief Summary
Evaluate HACOR socre utility and efficacy in predicting NIV and/or CPAP failure in patients with COVID-19 associated respiratory failure.
Propose adaptations to HACOR score based on the "state of art" of COVID-19
Detailed Description
Evaluate HACOR socre utility and efficacy in predicting NIV and/or CPAP failure in patients with COVID-19 associated respiratory failure.
Propose adaptations to HACOR score based on the "state of art" of COVID-19
- this adaptations may include radiologic aggravation and monitoring of CRF, ferritin, LDH, d-dimers, NT-proBNP, troponin I, GOT, GPT, blood count
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with acute respiratory failure due to COVID-19 who have initiated NIV or CPAP based on assistant clinician decision
Exclusion Criteria
- •Patients with imediate indication to invasive mechanical ventilation
- •Patients with any formal contraindication to noninvasive respiratory support
Outcomes
Primary Outcomes
HACOR score efficacy
Time Frame: 1 hour after initation of CPAP or NIV
Analyze if HACOR score is effective in predicting nonivasive ventilation failure in COVID-19 associated respiratory failure
HACOR score addaptation
Time Frame: 1 - 2 weeks
Analyze the role of possible variables to be added to HACOR score in order to improve efficay in COVID-19 patients
Secondary Outcomes
No secondary outcomes reported
Investigators
Miguel Filipe Martins de Matos Navarro Guia
Dr.
Hospital General Universitario Morales Meseguer